[go: up one dir, main page]

RU2011140251A - Иммунологические тесты на активность эндопептидаз с измененной нацеленностью - Google Patents

Иммунологические тесты на активность эндопептидаз с измененной нацеленностью Download PDF

Info

Publication number
RU2011140251A
RU2011140251A RU2011140251/15A RU2011140251A RU2011140251A RU 2011140251 A RU2011140251 A RU 2011140251A RU 2011140251/15 A RU2011140251/15 A RU 2011140251/15A RU 2011140251 A RU2011140251 A RU 2011140251A RU 2011140251 A RU2011140251 A RU 2011140251A
Authority
RU
Russia
Prior art keywords
snap
antibody
endopeptidase
bont
glutamine
Prior art date
Application number
RU2011140251/15A
Other languages
English (en)
Other versions
RU2543650C2 (ru
Inventor
Джоанн ВАНГ
Хонг ЖУ
Д. Дайана ХОДЖЕС
Эстер ФЕРНАНДЕС-САЛАС
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42244384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2011140251(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2011140251A publication Critical patent/RU2011140251A/ru
Application granted granted Critical
Publication of RU2543650C2 publication Critical patent/RU2543650C2/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/952—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

1. Способ детектирования активности эндопептидаз с измененной нацеленностью, включающий этапы:а. обработки клетки из стабильной клеточной линии образцом, содержащим эндопептидазу с измененной нацеленностью, причем указанная клетка из стабильной клеточной линии чувствительна к активности указанной эндопептидазы с измененной нацеленностью при концентрации эндопептидазы с измененной нацеленностью около 500 пМ или ниже;б. выделения из обработанной клетки компонента SNAP-25, содержащего продукт расщепления SNAP-25, карбоксильный конец которого соответствует глутамину разрезаемой связи в сайте расщепления токсином BoNT/A;в. осуществления контакта компонента SNAP-25 с анти-SNAP-25 антителом, иммобилизованным на твердофазной подложке,при этом анти-SNAP-25 антитело связывается с эпитопом, карбоксильный конец которого соответствует глутамину разрезаемой связи в сайте расщепления токсином BoNT/A, из продукта расщепления SNAP-25, анти-SNAP-25 антитело характеризуется константой скорости ассоциации для эпитопа из SNAP-25, не содержащего карбокси-концевой глутамин разрезаемой связи в сайте расщепления токсином BoNT/A, из продукта расщепления SNAP-25, составляющей менее 1×10Мс; и анти-SNAP-25 антитело характеризуется равновесной константой диссоциации для эпитопа, составляющей менее 0,450 нМ;г. детектирования присутствия комплекса антитело-антиген, включающего анти-SNAP-25 антитело и продукт расщепления SNAP-25, карбоксильный конец которого соответствует глутамину разрезаемой связи в сайте расщепления токсином BoNT/A;при этом детектирование с помощью указанного комплекса антитело-антиген является показателем активности эндопептидазы с измененной нацеленн�

Claims (7)

1. Способ детектирования активности эндопептидаз с измененной нацеленностью, включающий этапы:
а. обработки клетки из стабильной клеточной линии образцом, содержащим эндопептидазу с измененной нацеленностью, причем указанная клетка из стабильной клеточной линии чувствительна к активности указанной эндопептидазы с измененной нацеленностью при концентрации эндопептидазы с измененной нацеленностью около 500 пМ или ниже;
б. выделения из обработанной клетки компонента SNAP-25, содержащего продукт расщепления SNAP-25, карбоксильный конец которого соответствует глутамину разрезаемой связи в сайте расщепления токсином BoNT/A;
в. осуществления контакта компонента SNAP-25 с анти-SNAP-25 антителом, иммобилизованным на твердофазной подложке,
при этом анти-SNAP-25 антитело связывается с эпитопом, карбоксильный конец которого соответствует глутамину разрезаемой связи в сайте расщепления токсином BoNT/A, из продукта расщепления SNAP-25, анти-SNAP-25 антитело характеризуется константой скорости ассоциации для эпитопа из SNAP-25, не содержащего карбокси-концевой глутамин разрезаемой связи в сайте расщепления токсином BoNT/A, из продукта расщепления SNAP-25, составляющей менее 1×101 М-1 с-1; и анти-SNAP-25 антитело характеризуется равновесной константой диссоциации для эпитопа, составляющей менее 0,450 нМ;
г. детектирования присутствия комплекса антитело-антиген, включающего анти-SNAP-25 антитело и продукт расщепления SNAP-25, карбоксильный конец которого соответствует глутамину разрезаемой связи в сайте расщепления токсином BoNT/A;
при этом детектирование с помощью указанного комплекса антитело-антиген является показателем активности эндопептидазы с измененной нацеленностью.
2. Способ по п.1, отличающийся тем, что продукт расщепления SNAP-25 представляет собой SNAP-25197.
3. Способ по п.1, отличающийся тем, что присутствие комплекса антитело-антиген детектируют с использованием "сэндвич"-метода твердофазного ИФА.
4. Способ по п.1, отличающийся тем, что способ характеризуется отношением сигнала к шуму для нижней асимптоты, составляющим по меньшей мере 3:1, и отношением сигнала к шуму для верхней асимптоты, составляющим по меньшей мере 10:1.
5. Способ по п.1, отличающийся тем, что образец содержит не более 100 пМ эндопептидазы с измененной нацеленностью.
6. Способ по п.1, отличающийся тем, что клетка из стабильной клеточной линии чувствительна к ингибированию экзоцитоза эндопептидазой с измененной нацеленностью при концентрации эндопептидазы с измененной нацеленностью около 100 пМ или ниже.
7. Способ по п.1, отличающийся тем, что способ осуществляют в одноканальном режиме или многоканальном режиме.
RU2011140251/15A 2009-03-13 2010-03-12 Иммунологические тесты на активность эндопептидаз с измененной нацеленностью RU2543650C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16021709P 2009-03-13 2009-03-13
US61/160,217 2009-03-13
PCT/US2010/027244 WO2010105236A1 (en) 2009-03-13 2010-03-12 Immuno-based retargeted endopeptidase activity assays

Publications (2)

Publication Number Publication Date
RU2011140251A true RU2011140251A (ru) 2013-04-20
RU2543650C2 RU2543650C2 (ru) 2015-03-10

Family

ID=42244384

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011140251/15A RU2543650C2 (ru) 2009-03-13 2010-03-12 Иммунологические тесты на активность эндопептидаз с измененной нацеленностью

Country Status (24)

Country Link
US (7) US8455203B2 (ru)
EP (4) EP3281953B1 (ru)
JP (2) JP5826635B2 (ru)
KR (2) KR101797045B1 (ru)
CN (1) CN102422158B (ru)
AU (1) AU2010223912B2 (ru)
BR (1) BRPI1009115A2 (ru)
CA (1) CA2753894C (ru)
CL (1) CL2011002274A1 (ru)
CY (1) CY1122573T1 (ru)
DK (2) DK3281953T3 (ru)
ES (2) ES2440597T3 (ru)
HU (1) HUE047067T2 (ru)
IL (1) IL214793A (ru)
MX (1) MX2011009606A (ru)
MY (1) MY156334A (ru)
PH (1) PH12015500992A1 (ru)
PL (2) PL3281953T3 (ru)
PT (1) PT3281953T (ru)
RU (1) RU2543650C2 (ru)
SG (1) SG174353A1 (ru)
SI (1) SI3281953T1 (ru)
UA (1) UA104456C2 (ru)
WO (1) WO2010105236A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2683207C2 (ru) * 2013-10-25 2019-03-26 Биомэдисон, Инк. Ферментативный анализ с двойными флуорофорами для исследования ферментативной активности ботулинического нейротоксина

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
AU2011202219B2 (en) * 2005-12-01 2015-05-28 Allergan Inc. Fusion proteins
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
SI3031825T1 (sl) * 2008-03-14 2019-12-31 Allergan, Inc. Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti
KR101797045B1 (ko) * 2009-03-13 2017-11-13 알러간, 인코포레이티드 면역 기반 재표적화된 엔도펩티다제 활성 검정
KR102017327B1 (ko) 2009-03-13 2019-09-03 알러간, 인코포레이티드 면역 기반 보툴리눔 독소 혈청형 ａ 활성 검정에 유용한 세포
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EP3279335B1 (en) 2011-12-31 2021-03-10 Allergan, Inc. Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-a
US20170327810A1 (en) * 2012-08-27 2017-11-16 Ipsen Bioinnovation Limited Fusion proteins and methods for treating, preventing or ameliorating pain
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014059434A1 (en) * 2012-10-12 2014-04-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Assay for analyses of rabies virus glycoprotein
US11069427B2 (en) 2013-06-10 2021-07-20 Iogenetics, Llc Mathematical processes for determination of peptidase cleavage
WO2015088477A1 (en) * 2013-12-09 2015-06-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide substrates recognizable by type e botulinum neurotoxin
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US9943576B2 (en) 2014-04-30 2018-04-17 Allergan, Inc. Formulations of biologics for intravesical instillation
AU2015287964A1 (en) * 2014-07-07 2017-02-16 Allergan, Inc. Method of detecting cleaved SNAP25 in tissue samples
CA2954504A1 (en) * 2014-07-07 2016-01-14 Allergan, Inc. Method of detecting cleaved snap25 in tissue samples
CA2955492A1 (en) 2014-07-31 2016-02-04 Allergan, Inc. Formulations of biologics for intravesical instillation
TW202247855A (zh) 2016-09-13 2022-12-16 美商愛力根公司 非蛋白梭菌毒素組成物
CN106908610B (zh) * 2017-03-13 2018-11-02 绍兴康知生物科技有限公司 一种基于受体配体结合技术筛查吸食吗啡的试剂、制备方法及应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
ATE220421T1 (de) 1990-02-26 2002-07-15 Univ Leland Stanford Junior Identifizierung und expression von insekten- steroidrezeptor-dns-sequenzen
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US6432652B1 (en) 1992-08-13 2002-08-13 The Regents Of The University Of California Methods of screening modulators of opioid receptor activity
JP4208960B2 (ja) 1992-08-13 2009-01-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア オピオイドレセプター遺伝子
US20020061554A1 (en) 1992-08-13 2002-05-23 Evans Christopher J. Orphan opioid receptor and recombinant materials for its production
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
GB9411138D0 (en) * 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US5962637A (en) * 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
DE19702280A1 (de) 1997-01-23 1998-07-30 Bosch Gmbh Robert Verfahren zur Regelung der Leistungsverstärkung
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
WO2000034308A2 (en) 1998-12-10 2000-06-15 Washington University Protein transduction system and methods of use thereof
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
JP2002542498A (ja) 1999-04-22 2002-12-10 シグナス， インコーポレイテッド 干渉種を除去するための方法およびデバイス
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2380457A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
GB9930519D0 (en) 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
CA2417454A1 (en) 2000-07-31 2002-02-07 Active Motif Peptide-mediated delivery of molecules into cells
EE04529B1 (et) 2001-03-16 2005-08-15 Tartu �likool Termofiilne mikroorganismi tüvi Bacillus coagulans SIM-7 DSM 14043 ja meetod L(+)-laktaadi tootmiseks fermenteeritavatest suhkrutest ja nende segudest nimetatud mikroorganismi tüve abil
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7208285B2 (en) * 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
JP4262072B2 (ja) 2003-12-05 2009-05-13 株式会社日立製作所 自動車用補助機器制御装置
JP5178009B2 (ja) * 2003-12-19 2013-04-10 ウィスコンシン アルムニ リサーチ ファンデイション ボツリヌス神経毒素検出のための方法および複合体
CA2558758C (en) * 2004-02-24 2015-06-23 Allergan, Inc. Botulinum toxin screening assays
EP1761558A1 (en) 2004-06-30 2007-03-14 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
CA2575994A1 (en) 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a
CA2578911A1 (en) * 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
US7399607B2 (en) * 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US20070258992A1 (en) 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
US8512984B2 (en) * 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
WO2006059093A2 (en) 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
EP1877073B1 (en) 2004-12-01 2013-09-25 The Secretary of State for Health Non-cytotoxic protein conjugates
US8603779B2 (en) * 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ATE470857T1 (de) 2005-04-05 2010-06-15 Allergan Inc Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US7993656B2 (en) 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2009543558A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
SI3031825T1 (sl) * 2008-03-14 2019-12-31 Allergan, Inc. Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti
KR101797045B1 (ko) * 2009-03-13 2017-11-13 알러간, 인코포레이티드 면역 기반 재표적화된 엔도펩티다제 활성 검정

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2683207C2 (ru) * 2013-10-25 2019-03-26 Биомэдисон, Инк. Ферментативный анализ с двойными флуорофорами для исследования ферментативной активности ботулинического нейротоксина

Also Published As

Publication number Publication date
CN102422158B (zh) 2015-04-08
ES2440597T3 (es) 2014-03-07
US20150301050A1 (en) 2015-10-22
CL2011002274A1 (es) 2012-04-27
EP3281953A1 (en) 2018-02-14
US20240272160A1 (en) 2024-08-15
US20210172952A1 (en) 2021-06-10
PL3281953T3 (pl) 2020-05-18
MX2011009606A (es) 2011-09-28
US20100233741A1 (en) 2010-09-16
US8455203B2 (en) 2013-06-04
JP2016026303A (ja) 2016-02-12
MY156334A (en) 2016-02-15
ES2440597T9 (es) 2014-04-07
CA2753894C (en) 2017-12-05
EP2406629B1 (en) 2013-09-18
US20190324041A1 (en) 2019-10-24
EP3281953B1 (en) 2019-10-02
PT3281953T (pt) 2020-01-15
PL2406629T3 (pl) 2014-07-31
DK2406629T3 (da) 2014-01-13
AU2010223912A1 (en) 2011-09-15
US9651553B2 (en) 2017-05-16
CN102422158A (zh) 2012-04-18
DK2406629T5 (en) 2014-03-03
US20130267010A1 (en) 2013-10-10
JP6254132B2 (ja) 2017-12-27
US10900967B2 (en) 2021-01-26
KR101923847B1 (ko) 2018-11-29
RU2543650C2 (ru) 2015-03-10
BRPI1009115A2 (pt) 2015-10-06
IL214793A (en) 2015-06-30
KR20170126032A (ko) 2017-11-15
CY1122573T1 (el) 2021-01-27
EP2568285A1 (en) 2013-03-13
US20170248602A1 (en) 2017-08-31
CA2753894A1 (en) 2010-09-16
JP2012520470A (ja) 2012-09-06
DK3281953T3 (da) 2020-01-20
EP2568285B1 (en) 2019-12-25
ES2770033T3 (es) 2020-06-30
EP2406629B9 (en) 2014-03-26
KR101797045B1 (ko) 2017-11-13
HUE047067T2 (hu) 2020-04-28
IL214793A0 (en) 2011-11-30
HK1169855A1 (en) 2013-02-08
SI3281953T1 (sl) 2020-03-31
AU2010223912B2 (en) 2015-09-24
UA104456C2 (ru) 2014-02-10
EP2406629A1 (en) 2012-01-18
EP2570809A1 (en) 2013-03-20
PH12015500992A1 (en) 2015-09-07
US10345306B2 (en) 2019-07-09
WO2010105236A1 (en) 2010-09-16
KR20110139260A (ko) 2011-12-28
SG174353A1 (en) 2011-11-28
JP5826635B2 (ja) 2015-12-02

Similar Documents

Publication Publication Date Title
RU2011140251A (ru) Иммунологические тесты на активность эндопептидаз с измененной нацеленностью
RU2010140478A (ru) Иммунологические анализы активности ботулинического токсина серотипа а
Yang et al. Development of novel portable and reusable fiber optical chemiluminescent biosensor and its application for sensitive detection of microcystin-LR
Loo et al. Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers
CN103048465B (zh) 一种il-6微孔板式化学发光检测试剂盒及其制备方法
JP2015143689A5 (ja) 免疫基盤ボツリヌス毒素血清ａ型活性アッセイ
NZ603492A (en) Humanized anti-factor d antibodies and uses thereof
MX2009013411A (es) Deteccion de antigenos transportados por eritrocitos y de anticuerpos anti-eritrocitos.
GB201105828D0 (en) A device for detecting an analyte
Damoiseaux et al. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis
Lévêque et al. An optical biosensor assay for rapid dual detection of Botulinum neurotoxins A and E
CA2757637C (en) Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
Lévêque et al. Direct biosensor detection of botulinum neurotoxin endopeptidase activity in sera from patients with type A botulism
Arevalo et al. Unraveling autoimmune and neurodegenerative diseases by amperometric serological detection of antibodies against aquaporin-4
Dekimpe et al. Determination of anti‐ADAMTS‐13 autoantibody titers in ELISA: Influence of ADAMTS‐13 presentation and autoantibody detection
EP2565647A4 (en) REAGENT TO TEST AN ANTIBODY AGAINST TREPONEMA PALLIDUM
EP1832654A4 (en) MONOCLONAL ANTIBODY TO HUMAN SOLUBLE FIBRINE AND IMMUNOLOGICAL TEST PROCEDURE USING THE ANTIBODY
US9213026B2 (en) System for determining unprocessed and partially processed neurotoxin type A
RU2009124225A (ru) Мышиные моноклональные антитела, связывающиеся с антигеном f1 из yersinia pestis, способ их получения с использованием дрожжей, способ и набор для детекции yersinia pestis
Teller et al. Development of a bifunctional sensor using haptenized acetylcholinesterase and application for the detection of cocaine and organophosphates
WO2012006540A3 (en) Improving the efficiency of prion conversion in vitro and sensitivity of prion detection
WO2004027423A1 (ja) コラーゲンの測定方法
US20160257988A1 (en) Indicator Molecules For Use In Detecting Enzyme Cleavage Activity
Schelpe et al. Anti-cysteine-rich/spacer or anti-CUB1 antibodies that increase ADAMTS13 activity act by allosterically enhancing metalloprotease domain function
Manahan-Suyom et al. Development of diffractive optics technology-based immunoassay protocol and its application in the detection of Entamoeba histolytica infections

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20141008

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20141112

MM4A The patent is invalid due to non-payment of fees

Effective date: 20210313